Replies to post #1087 on Power 3 Medical Products Inc (fka PWRM)

[garyhalvo]

Power3 Medical Products, Inc. (OTCBB:PWRM) is pleased to announce that the company will be a sponsor and have an exhibit booth at the 4th Annual Conference of the Alzheimer's Drug Discovery Foundation on Drug Discovery for Neurodegeneration in Houston on February 1-2, 2010.

"This meeting is particularly appropriate for the company. The NuroPro(R) blood protein biomarkers and tests for early detection, differential diagnosis, and monitoring of therapeutic response of Alzheimer's disease, Parkinson's disease and ALS are progressing through clinical validation trials," said Dr. Ira L. Goldknopf, Chief Scientific Officer. "Power3 remains at the forefront of this area."

"I am proud of the continued progress of Power3 in the neurodegenerative diseases. We are continuing publication and promotion of the exciting results of our clinical validation trials in these areas and are glad to have the opportunity to move into the marketing area of drug discovery," said Helen R. Park, CEO of Power3 Medical. "We are eager to make an impact in drug discovery for neurodegenerative disease and think our presence at this conference will provide inroads into that area."

[Tommy105]

Biotech Stock Alert for Power 3 Medical Products Inc. Issued by Beacon Equity
http://www.tradingmarkets.com/news/stock-alert/pwrm_pwrm_biotech-stock-alert-for-power-3-medical-products-inc-issued-by-beacon-equity-745034.html

Power 3 Medical Products Inc. (PWRM) is a development-stage biotechnology company specializing in the early detection of breast cancer, Alzheimer's disease, Lou Gehrig's disease, Parkinson's disease, leukemia, gastrointestinal disease and metabolic syndrome. The Company focuses upon the study of proteomics, which identifies 334 protein biomarkers for the above-named diseases.

In the report, the analyst notes:

"The Company presently operates at a deficit, with minimal operating revenues from the sale of its products and services at this time. Management is pursuing third-party licensing, collaboration and distribution agreements to generate revenue from its disease diagnosis biomarker and drug resistance identification systems. The Company's proprietary identification system aids in the areas of various cancers, neurodegenerative and neuromuscular diseases.

"The Company's goal is to complete phase II of its testing to identify Alzheimer's and Parkinson's disease. Partnering with Transgenomic Inc., the Company expects to complete phase II and begin to commercialize its testing products during the first quarter of 2010.

"The Company stated in its latest 10-Q of November 16, that it seeks grants and other sources of funding to take its BC-SeraPro(TM) and NuroPro Blood Test to full commercialization and to continue operations."

To read the entire report visit: http://www.beaconequity.com/i/PWRM